Overview

• Pfizer posted second-quarter adjusted earnings per share of $0.78, surpassing the 57-cent consensus and up from 60 cents a year earlier.
• Revenue for the quarter rose 10% year-over-year to $14.65 billion, exceeding the $13.56 billion analysts expected.
• The company lifted its full-year adjusted profit guidance to $2.90–$3.10 per share while maintaining a revenue forecast of $61–$64 billion.
• The updated outlook includes a one-time $1.35 billion Q3 charge related to the 3SBio licensing deal and incorporates existing tariffs plus potential U.S. drug-pricing measures.
• Pfizer’s cost-cutting initiatives are on track to deliver about $7.7 billion in savings by 2027, and Comirnaty and Paxlovid sales rose 95% and 71%, respectively.